Empire Financial Management Company LLC Purchases Shares of 5,940 Bristol-Myers Squibb (NYSE:BMY)

Empire Financial Management Company LLC acquired a new stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 5,940 shares of the biopharmaceutical company's stock, valued at approximately $336,000.

Other large investors also recently modified their holdings of the company. Voya Investment Management LLC boosted its stake in Bristol-Myers Squibb by 96.6% in the 4th quarter. Voya Investment Management LLC now owns 1,925,677 shares of the biopharmaceutical company's stock worth $108,916,000 after purchasing an additional 946,356 shares during the period. Integrated Wealth Concepts LLC boosted its position in shares of Bristol-Myers Squibb by 19.4% during the fourth quarter. Integrated Wealth Concepts LLC now owns 65,346 shares of the biopharmaceutical company's stock worth $3,696,000 after acquiring an additional 10,616 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Bristol-Myers Squibb by 72.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 7,769,227 shares of the biopharmaceutical company's stock valued at $439,427,000 after acquiring an additional 3,275,061 shares in the last quarter. Syon Capital LLC increased its holdings in Bristol-Myers Squibb by 37.2% in the 4th quarter. Syon Capital LLC now owns 15,982 shares of the biopharmaceutical company's stock valued at $904,000 after acquiring an additional 4,335 shares during the last quarter. Finally, Coppell Advisory Solutions LLC lifted its stake in Bristol-Myers Squibb by 43.8% in the 4th quarter. Coppell Advisory Solutions LLC now owns 1,560 shares of the biopharmaceutical company's stock worth $87,000 after purchasing an additional 475 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Up 1.1 %

Bristol-Myers Squibb stock traded up $0.55 during midday trading on Monday, reaching $48.45. The company's stock had a trading volume of 18,435,319 shares, compared to its average volume of 12,950,872. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The stock has a market capitalization of $98.58 billion, a P/E ratio of -10.96, a PEG ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock's 50-day simple moving average is $56.37 and its 200-day simple moving average is $56.53.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period last year, the business earned ($4.40) EPS. Bristol-Myers Squibb's revenue for the quarter was down 5.6% on a year-over-year basis. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.12%. Bristol-Myers Squibb's payout ratio is presently 92.88%.

Insider Activity

In other news, EVP Samit Hirawat bought 1,823 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. UBS Group reduced their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Truist Financial upped their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Jefferies Financial Group cut their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.